Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription

Circulation

Volumn 102, Issue 25, 2000, Pages 3104-3110

  Laufs, Ulrich ^a   Endres, Matthias ^b   Custodis, Florian ^a   Gertz, Karen ^b   Nickenig, Georg ^a   Liao, James K ^c   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Endothelium; Nitric oxide; Rho GTPase; Statins

Indexed keywords

ATORVASTATIN; COMPACTIN; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; NITRIC OXIDE; RHO FACTOR; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATTLE; CONTROLLED STUDY; CYTOSKELETON; ENZYME SYNTHESIS; GENE EXPRESSION REGULATION; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0034687606     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.25.3104     Document Type: Article

References (33)

1. Current perspectives on statins
2. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
3. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
4. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?
5. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
6. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
7. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
8. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
9. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
10. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterollowering actions
11. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects
12. Neuroprotection mediated by changes in the endothelial actin cytoskeleton
13. Endothelium and acute coronary syndromes
14. Increased thrombotic vascular events after change of statin
15. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase
16. Regulation of the mevalonate pathway
17. Bacterial toxins that target rho proteins
18. Rho GTPases and signaling networks
19. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and rho proteins
20. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down- regulation of p27(Kipl)
21. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes
22. Myocyte hypertrophy: The long and winding RhoA'd
23. Mechanotransduction of rat aortic vascular smooth muscle cells requires RhoA and intact actin filaments
24. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton
25. Modulation of bradykinin receptor ligand binding affinity and its coupled G-proteins by nitric oxide
26. Rho GTPases and the actin cytoskeleton
27. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering
28. Rho and rho kinase mediate thrombm-stimulated vascular smooth muscle cell DNA synthesis and migration
29. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis
30. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats
31. Inhibition of proinflammatory cytokine production by pravastatin
32. Stimulation of bone formation in vitro and in rodents by statins
33. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revascularization Treatment Investigators